Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
XTalks
AUGUST 17, 2020
This typically involves taking T cells from the body, engineering chimeric receptor antigens (CAR) and inserting them into the cells, expanding the cells ex vivo and injecting them back into the body. Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells. Image from Cue Biopharma.
98 
Let's personalize your content